Post-void residual (PVR) volume and urinary retention assessments in a randomized, double-blind, Phase IIIb trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to 4-week solifenacin monotherapy (BESIDE)

Drake M1, MacDiarmid S2, Al-Shukri S3, Barkin J4, Fianu-Jonasson A5, Grise P6, Herschorn S4, Huang M7, Stölzel M7, Hemsted C7, Siddiqui E7

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 281
Overactive Bladder and Paediatrics
Scientific Podium Short Oral Session 18
Thursday 15th September 2016
12:00 - 12:07
Hall B5
Detrusor Overactivity Clinical Trial Incontinence
1. University of Bristol and Bristol Urological Institute, 2. Alliance Urology Specialists, 3. Pavolv 1st State Medical University, 4. University of Toronto, 5. Karolinksa University Hospital, 6. Rouen University Hospital, 7. Astellas
Presenter
S

Sender Herschorn

Links

Abstract

28/03/2024 14:50:13